MX338572B - Derivados de 4-(p-quinonil)-2-hidroxibutanamida para tratamiento de enfermedades mitocondriales. - Google Patents
Derivados de 4-(p-quinonil)-2-hidroxibutanamida para tratamiento de enfermedades mitocondriales.Info
- Publication number
- MX338572B MX338572B MX2013012276A MX2013012276A MX338572B MX 338572 B MX338572 B MX 338572B MX 2013012276 A MX2013012276 A MX 2013012276A MX 2013012276 A MX2013012276 A MX 2013012276A MX 338572 B MX338572 B MX 338572B
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- disclosed
- treatment
- compounds useful
- mitochondrial diseases
- Prior art date
Links
- 208000012268 mitochondrial disease Diseases 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000024412 Friedreich ataxia Diseases 0.000 abstract 2
- 208000032087 Hereditary Leber Optic Atrophy Diseases 0.000 abstract 2
- 206010048804 Kearns-Sayre syndrome Diseases 0.000 abstract 2
- 201000000639 Leber hereditary optic neuropathy Diseases 0.000 abstract 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 2
- 239000000090 biomarker Substances 0.000 abstract 2
- 206010003805 Autism Diseases 0.000 abstract 1
- 208000020706 Autistic disease Diseases 0.000 abstract 1
- 208000014644 Brain disease Diseases 0.000 abstract 1
- 208000032274 Encephalopathy Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 201000002169 Mitochondrial myopathy Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000012202 Pervasive developmental disease Diseases 0.000 abstract 1
- 208000029560 autism spectrum disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 208000023692 inborn mitochondrial myopathy Diseases 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
- C07C235/80—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms having carbon atoms of carboxamide groups and keto groups bound to the same carbon atom, e.g. acetoacetamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
- C07C235/76—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
- C07C235/78—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton the carbon skeleton containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/46—Oxygen atoms
- C07D213/50—Ketonic radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/46—Oxygen atoms
- C07D213/51—Acetal radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D223/04—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with only hydrogen atoms, halogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
- C07D295/112—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
- C07D295/116—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings with the doubly bound oxygen or sulfur atoms directly attached to a carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- C07D311/66—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Pyrrole Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Pyrane Compounds (AREA)
- Furan Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se describen métodos de tratar o suprimir enfermedades mitocondriales, tales como ataxia de Friedreich (DRDA), Neuropatía Óptica Hereditaria de Leber (LHON), miopatía mitocondrial, encefalopatía, lactacidosis, y derrames cerebrales (MELAS) y Síndrome de Kearns-Sayre (KSS), así como compuestos útiles en métodos de la invención, tales como deriados de 4-(p-quinolil)-2-hidroxibutanamida. Tmbén se desriben métodos y compuestos útiles en tratar otros trastornos tales como Esclerosis de Lateral de Amiotrófica (ALS), enfermedad de Huntington y enfermedad de Parkinson, y trastornos pervasivos del desarrollo tales como autismo. Tambén se describen biomaracadores de energía útiles en la valoración del estado metabolico de un sujeto y la eficacia de tratamiento. Tambén se describen métodos de modular, normalizar o mejorar los biomaracadores de energía, así como compuestos útiles para tales métodos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US212607P | 2007-11-06 | 2007-11-06 | |
US212707P | 2007-11-06 | 2007-11-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX338572B true MX338572B (es) | 2016-04-22 |
Family
ID=40474999
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2010004622A MX2010004622A (es) | 2007-11-06 | 2008-11-04 | Derivados de 4-(p-quinonil)-2-hidroxibutanamida para tratamiento de enfermedades mitocondriales. |
MX2013012276A MX338572B (es) | 2007-11-06 | 2010-04-27 | Derivados de 4-(p-quinonil)-2-hidroxibutanamida para tratamiento de enfermedades mitocondriales. |
MX2020004146A MX2020004146A (es) | 2007-11-06 | 2010-04-27 | Derivados de 4-(p-quinonil)-2-hidroxibutanamida para tratamiento de enfermedades mitocondriales. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2010004622A MX2010004622A (es) | 2007-11-06 | 2008-11-04 | Derivados de 4-(p-quinonil)-2-hidroxibutanamida para tratamiento de enfermedades mitocondriales. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020004146A MX2020004146A (es) | 2007-11-06 | 2010-04-27 | Derivados de 4-(p-quinonil)-2-hidroxibutanamida para tratamiento de enfermedades mitocondriales. |
Country Status (13)
Country | Link |
---|---|
US (7) | US7968746B2 (es) |
EP (4) | EP2220030B1 (es) |
JP (8) | JP5755881B2 (es) |
CA (1) | CA2704473C (es) |
DK (2) | DK3456707T3 (es) |
EA (2) | EA038941B1 (es) |
ES (1) | ES2564179T3 (es) |
HK (1) | HK1143804A1 (es) |
HU (1) | HUE028502T2 (es) |
MX (3) | MX2010004622A (es) |
PL (2) | PL2220030T3 (es) |
SI (2) | SI3456707T1 (es) |
WO (1) | WO2009061744A2 (es) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7514461B2 (en) | 2003-09-19 | 2009-04-07 | Edison Pharmaceuticals, Inc. | Chroman derivatives |
DK1888059T3 (en) * | 2005-06-01 | 2015-03-30 | Edison Pharmaceuticals Inc | Redox-active therapeutic products for the treatment of mitochondrial diseases and other conditions as well as modulation of energy biomarkers |
EA019675B1 (ru) | 2006-02-22 | 2014-05-30 | Эдисон Фармасьютикалз, Инк. | Редокс-активные терапевтические средства для лечения митохондриальных заболеваний и модуляции биомаркера коэнзима q |
EP2220030B1 (en) | 2007-11-06 | 2016-01-13 | Edison Pharmaceuticals, Inc. | 4- (p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases |
WO2009089224A1 (en) | 2008-01-08 | 2009-07-16 | Edison Pharmaceuticals, Inc. | (HET) ARYL-p-QUINONE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES |
EP2262519A4 (en) * | 2008-03-05 | 2011-03-23 | Edison Pharmaceuticals Inc | TREATMENT OF HEARING AND BALANCE DEFICIENCIES WITH THERAPEUTIC AGENTS WITH REDOX ACTIVITY |
WO2009111576A2 (en) | 2008-03-05 | 2009-09-11 | Edison Pharmaceuticals, Inc. | 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES |
US8716486B2 (en) * | 2008-06-25 | 2014-05-06 | Edison Pharmaceuticals, Inc. | 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases |
US8314153B2 (en) | 2008-09-10 | 2012-11-20 | Edison Pharmaceuticals, Inc. | Treatment of pervasive developmental disorders with redox-active therapeutics |
US10039722B2 (en) | 2008-10-14 | 2018-08-07 | Bioelectron Technology Corporation | Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells |
PL2963006T3 (pl) | 2008-10-28 | 2019-01-31 | Bioelectron Technology Corporation | Kompozycja zawierająca chinon alfa-tokotrienolu, i jego związki pośrednie |
NO2424495T3 (es) | 2009-04-28 | 2018-06-16 | ||
NO2470168T3 (es) * | 2009-08-26 | 2018-06-30 | ||
DK3072524T3 (en) | 2010-10-07 | 2018-04-09 | California Inst Of Techn | Probiotic treatments for autism |
WO2012133896A1 (ja) | 2011-03-31 | 2012-10-04 | YANO Takamitsu | ポリアミド化合物及びミトコンドリア遺伝子疾患治療用医薬組成物 |
US9428478B2 (en) | 2011-06-13 | 2016-08-30 | Emory University | Piperazine derivatives, compositions, and uses related thereto |
US9464016B2 (en) | 2011-06-14 | 2016-10-11 | Edison Pharmaceuticals, Inc. | Catechol derivatives for treatment of oxidative stress diseases |
EP2734512B1 (en) | 2011-07-19 | 2019-11-20 | Bioelectron Technology Corporation | Methods for selective oxidation of alpha tocotrienol in the presence of non-alpha tocotrienols |
CN104662011B (zh) * | 2012-07-12 | 2017-09-29 | 康尊知识产权公司 | 治疗线粒体疾病的色满衍生物 |
IN2015MN00114A (es) | 2012-07-12 | 2015-10-16 | Khondrion Ip B V | |
CN104768560A (zh) * | 2012-08-29 | 2015-07-08 | 加州理工学院 | 孤独症谱系障碍的诊断和治疗 |
CA2883882A1 (en) | 2012-09-07 | 2014-03-13 | Edison Pharmaceuticals, Inc. | Benzoquinone derivatives for treating oxidative stress disorders |
EP2911656B1 (en) * | 2012-10-23 | 2020-12-02 | Nicox SA | Quinone based nitric oxide donating compounds for ophthalmic use |
NL2010010C2 (en) * | 2012-12-19 | 2014-06-23 | Sulfateq B V | Compounds for protection of cells. |
US9296712B2 (en) | 2013-03-15 | 2016-03-29 | Edison Pharmaceuticals, Inc. | Resorufin derivatives for treatment of oxidative stress disorders |
EP2970158B1 (en) | 2013-03-15 | 2019-02-20 | BioElectron Technology Corporation | Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders |
US9868711B2 (en) | 2013-03-15 | 2018-01-16 | Bioelectron Technology Corporation | Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders |
US9670170B2 (en) | 2013-03-15 | 2017-06-06 | Bioelectron Technology Corporation | Resorufin derivatives for treatment of oxidative stress disorders |
CN107106616A (zh) | 2014-10-30 | 2017-08-29 | 加利福尼亚技术学院 | 包括改善神经发育障碍行为的细菌的组合物和方法 |
WO2016069801A1 (en) | 2014-10-30 | 2016-05-06 | California Institute Of Technology | Compositions and methods comprising bacteria for improving behavior in neurodecelopmental disorders |
SI3233786T1 (sl) | 2014-12-16 | 2022-08-31 | PTC Therapeutics, Inc., | Polimorfne in amorfne oblike (R)-2-hidroksi-2-metil-4-(2,4,5-trimetil- 3,6-dioksocikloheksa-1,4-dienil)butanamida |
JP2018500317A (ja) * | 2014-12-16 | 2018-01-11 | バイオエレクトロン テクノロジー コーポレイション | トロロックスのキラル分割のための方法 |
EP3359521A1 (en) * | 2015-10-08 | 2018-08-15 | Khondrion Ip B.V. | Novel compounds for treating mitochondrial disease |
US10745371B2 (en) | 2015-12-16 | 2020-08-18 | Ptc Therapeutics, Inc. | Methods for enriching alpha-tocotrienol from mixed tocol compositions |
US10703701B2 (en) | 2015-12-17 | 2020-07-07 | Ptc Therapeutics, Inc. | Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders |
CA3019342A1 (en) | 2016-03-30 | 2017-10-05 | Wisconsin Alumni Research Foundation | Methods and compositions for modulating frataxin expression |
EP3465212A4 (en) | 2016-05-23 | 2020-01-08 | California Institute of Technology | REGULAR FLORAL REGULATION FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES |
JP2018083799A (ja) | 2016-11-15 | 2018-05-31 | バイオエレクトロン テクノロジー コーポレイション | 2−置換アミノ−ナフト[1,2−d]イミダゾール−5−オン化合物またはその製薬学上許容される塩 |
US11759533B2 (en) | 2017-03-29 | 2023-09-19 | Wisconsin Alumni Research Foundation | Methods and compositions for modulating gene expression |
KR102660473B1 (ko) * | 2017-04-05 | 2024-04-24 | 콘드리온 아이피 비.브이. | 미토콘드리아 질환의 신규 치료 |
DK3615502T3 (da) | 2017-04-21 | 2023-09-25 | Univ Tasmania | Terapeutiske forbindelser og fremgangsmåder |
EP3624782A4 (en) | 2017-05-15 | 2021-05-05 | Axial Biotherapeutics, Inc. | INHIBITORS OF MICROBIALLY INDUCED AMYLOID |
CN111417393A (zh) * | 2017-11-22 | 2020-07-14 | 康尊知识产权公司 | 作为mPGES-1抑制剂的化合物 |
EP3830081B1 (en) | 2018-07-31 | 2024-05-22 | Novartis AG | Crystalline forms of a lta4h inhibitor |
JP2022505257A (ja) | 2018-10-17 | 2022-01-14 | ピーティーシー セラピューティクス, インコーポレイテッド | α-シヌクレイノパチー、タウオパチー、および他の障害を抑制および処置するための2,3,5-トリメチル-6-ノニルシクロヘキサ-2,5-ジエン-1,4-ジオン |
NL2024431B1 (en) * | 2019-12-11 | 2021-09-07 | Sulfateq Bv | Compounds for treatment of alzheimer’s disease |
CN115066420A (zh) | 2020-02-21 | 2022-09-16 | 住友制药株式会社 | 光学拆分的Trolox中间体和其制造方法 |
JP2024525232A (ja) | 2021-07-08 | 2024-07-10 | ピーティーシー セラピューティクス、インコーポレイテッド | 2,3,5-トリメチル-6-ノニルシクロヘキサ-2,5-ジエン-1,4-ジオンを含む医薬組成物 |
CN115417789B (zh) * | 2022-09-03 | 2023-08-04 | 郑州大学 | 一种治疗帕金森氏病的化合物、其制备方法以及复方药物组合物和应用 |
Family Cites Families (128)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US683982A (en) * | 1901-04-29 | 1901-10-08 | George Dudley Pogue | Incandescent-lamp attachment. |
US3947473A (en) | 1972-12-22 | 1976-03-30 | Hoffman-La Roche Inc. | Antioxidant chroman compounds |
US4026907A (en) | 1973-11-19 | 1977-05-31 | Hoffmann-La Roche Inc. | Antioxidant chroman compounds |
US4018799A (en) | 1973-11-19 | 1977-04-19 | Hoffmann-La Roche Inc. | Antioxidant chroman compounds |
JPS5640651A (en) | 1979-09-12 | 1981-04-16 | Takeda Chem Ind Ltd | Quinone compound and its preparation |
CA1338012C (en) | 1987-04-27 | 1996-01-30 | John Michael Mccall | Pharmaceutically active amines |
US5272180A (en) | 1987-07-29 | 1993-12-21 | Takeda Chemical Industries, Ltd. | Cell proliferation inhibitor |
AT395947B (de) | 1989-02-03 | 1993-04-26 | Tyrolia Freizeitgeraete | Skibindung |
JPH02250831A (ja) * | 1989-03-23 | 1990-10-08 | Kuraray Co Ltd | 3,4―ジヒドロ―2h―ベンゾピラン誘導体及びそれを有効成分とする抗消化性潰瘍剤 |
DE4000397A1 (de) | 1990-01-09 | 1991-07-11 | Hoechst Ag | Lipidselektive antioxidantien sowie deren herstellung und verwendung |
US5348973A (en) | 1990-10-09 | 1994-09-20 | Rhone-Poulenc Chimie | Resolution of hydroxychroman-2-carboxylic acid esters by enantiomeric hydrolysis |
FR2676056B1 (fr) * | 1991-05-03 | 1993-07-16 | Adir | Nouveaux derives du benzopyranne leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
FR2696743B1 (fr) * | 1992-10-12 | 1994-12-23 | Adir | Nouveaux composés de thiazolidine dione, leur procédé de préparation et les compositions pharmaceutiques les contenant. |
JPH08104685A (ja) * | 1993-09-03 | 1996-04-23 | Takeda Chem Ind Ltd | ラクトール誘導体、その製造法および用途 |
JP2503198B2 (ja) | 1993-09-24 | 1996-06-05 | 株式会社富士商会 | 受水槽給水配管系の定水位弁 |
US6150402A (en) | 1994-08-15 | 2000-11-21 | Loma Linda University Medical Center | Natriuretic compounds |
CA2207333C (en) | 1994-12-28 | 2006-10-17 | Janssen Pharmaceutica, Naamloze Vennootschap | Use of nebivolol as an anti-atherogenic |
DE69622569T2 (de) | 1995-08-21 | 2003-01-16 | Takeda Chemical Industries, Ltd. | Quinoneverbindung, seine herstellung und anwendung. |
US6232060B1 (en) | 1996-01-19 | 2001-05-15 | Galileo Laboratories, Inc. | Assay system for anti-stress agents |
US5801159A (en) | 1996-02-23 | 1998-09-01 | Galileo Laboratories, Inc. | Method and composition for inhibiting cellular irreversible changes due to stress |
EP0915696B1 (en) | 1996-07-11 | 2002-05-29 | Takeda Chemical Industries, Ltd. | ANTI-beta-AMYLOID PROTEIN-INDUCED CYTOTOXICITY COMPOSITION |
AU716992B2 (en) * | 1996-09-19 | 2000-03-16 | Japan Energy Corporation | Hydroquinone derivative and pharmaceutical use thereof |
JP3093170B2 (ja) * | 1996-09-19 | 2000-10-03 | 株式会社ジャパンエナジー | ヒドロキノン誘導体及びその医薬用途 |
FR2756284B1 (fr) * | 1996-11-26 | 2000-04-28 | Adir | Nouveaux derives du benzopyrane, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US6291464B1 (en) * | 1997-02-17 | 2001-09-18 | Fujisawa Pharmaceutical Co., Ltd. | Aminopiperazine derivatives |
JP3913329B2 (ja) | 1997-09-11 | 2007-05-09 | 株式会社クラレ | (±)−クロマンカルボン酸の光学分割法 |
JP4331284B2 (ja) | 1998-04-01 | 2009-09-16 | 株式会社ダイヘン | 短絡移行式ア−ク溶接方法 |
JP2000281656A (ja) * | 1998-08-05 | 2000-10-10 | Nippon Soda Co Ltd | フェニルアゾール化合物、製造法および抗高脂血症薬 |
FR2783519B1 (fr) | 1998-09-23 | 2003-01-24 | Sod Conseils Rech Applic | Nouveaux derives d'amidines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant |
EP1006108A1 (en) * | 1998-12-01 | 2000-06-07 | Cerebrus Pharmaceuticals Limited | 3-Hydroxy-2(1H)-pyridinone or 3-hydroxy-4(1H)-pyridinone derivatives useful as reactive oxygen species (ROS) scavengers |
JP2000191616A (ja) * | 1998-12-24 | 2000-07-11 | Senju Pharmaceut Co Ltd | 新規ジペプチジルアルデヒド誘導体およびそれを含有する医薬 |
WO2000078296A2 (en) | 1999-06-17 | 2000-12-28 | Basf Aktiengesellschaft | Tocotrienol and/or tocotrienol derivatives for the treatment or prophylaxis of glutamate- and/or calcium-induced disorders |
US6528042B1 (en) | 1999-10-08 | 2003-03-04 | Galileo Laboratories, Inc. | Compositions of flavonoids for use as cytoprotectants and methods of making and using them |
US6426362B1 (en) | 1999-10-08 | 2002-07-30 | Galileo Laboratories, Inc. | Formulations of tocopherols and methods of making and using them |
IL149177A0 (en) | 1999-11-05 | 2002-11-10 | Sod Conseils Rech Applic | Novel heterocyclic compounds and their use as medicines |
ATE355087T1 (de) * | 2000-10-24 | 2006-03-15 | Cis Bio Int | Stabilisierung von radiopharmazeutischen zusammensetzungen mit einem hydrophilen thioether oder einem hydrophilen 6-hydroxy-chroman |
US7034054B2 (en) | 2000-12-15 | 2006-04-25 | Galileo Pharmaceuticals, Inc. | Methods for the prevention and treatment of cerebral ischemia using non-alpha tocopherols |
US20020132845A1 (en) | 2000-12-15 | 2002-09-19 | Miller Guy Michael | Compositions and methods for the prevention and treatment of tissue ischemia |
US6608196B2 (en) | 2001-05-03 | 2003-08-19 | Galileo Pharmaceuticals, Inc. | Process for solid supported synthesis of pyruvate-derived compounds |
NZ513547A (en) | 2001-08-13 | 2002-09-27 | Antipodean Biotechnology Ltd | Synthesis of triphenylphosphonium quinols (e.g. mitoquinol) and/or quinones (e.g. mitoquinone) |
WO2003015494A2 (en) | 2001-08-21 | 2003-02-27 | Galileo Pharmaceuticals, Inc. | Tocopherol enriched compositions and amelioration of inflammatory symptoms |
WO2003043570A2 (en) | 2001-11-15 | 2003-05-30 | Galileo Laboratories, Inc. | Formulations and methods for treatment or amelioration of inflammatory conditions |
JP4412586B2 (ja) * | 2002-01-08 | 2010-02-10 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | エポネマイシンおよびエポキソマイシン類似物およびそれらの用途 |
US6667330B2 (en) | 2002-01-31 | 2003-12-23 | Galileo Pharmaceuticals, Inc. | Furanone derivatives |
US6653346B1 (en) | 2002-02-07 | 2003-11-25 | Galileo Pharmaceuticals, Inc. | Cytoprotective benzofuran derivatives |
US7078541B2 (en) | 2002-02-07 | 2006-07-18 | Galileo Pharmaceuticals, Inc. | Benzofuran derivatives |
GB0204232D0 (en) | 2002-02-22 | 2002-04-10 | Isis Innovation | Assay |
ATE328283T1 (de) | 2002-07-01 | 2006-06-15 | Santhera Pharmaceuticals Ch | Screeningverfahren und verbindungen zur behandlung von friedreich ataxia |
US7491312B2 (en) | 2002-10-30 | 2009-02-17 | Edison Pharmaceuticals, Inc. | Identifying therapeutic compounds based on their physical-chemical properties |
WO2004045534A2 (en) | 2002-11-15 | 2004-06-03 | Galileo Pharmaceuticals, Inc. | Chroman derivatives for the reduction of inflammation symptoms |
EP1454627A1 (en) | 2003-03-06 | 2004-09-08 | MyoContract Ltd. | Alpha-Keto carbonyl calpain inhibitors |
US7514461B2 (en) | 2003-09-19 | 2009-04-07 | Edison Pharmaceuticals, Inc. | Chroman derivatives |
CN1902181A (zh) * | 2003-10-28 | 2007-01-24 | 沃泰克斯药物股份有限公司 | 可用作离子通道调控剂的苯并咪唑 |
US7393662B2 (en) | 2004-09-03 | 2008-07-01 | Centocor, Inc. | Human EPO mimetic hinge core mimetibodies, compositions, methods and uses |
FR2875803B1 (fr) | 2004-09-24 | 2006-11-24 | Catalys Sarl | Preparation de composes phenol-amides a proprietes antioxydantes |
GB0503434D0 (en) * | 2005-02-18 | 2005-03-30 | Senexis Ltd | Amyloid-binding peptides, analogues and uses thereof |
DK1888059T3 (en) | 2005-06-01 | 2015-03-30 | Edison Pharmaceuticals Inc | Redox-active therapeutic products for the treatment of mitochondrial diseases and other conditions as well as modulation of energy biomarkers |
DK1933821T3 (da) | 2005-09-15 | 2020-10-26 | Ptc Therapeutics Inc | Halevarianter af redox-aktive terapeutika til behandling af mitokondriesygdomme og andre tilstande og modulation af energibiomarkører |
US20070208086A1 (en) * | 2006-02-15 | 2007-09-06 | The Regents Of The University Of California | Ubiquinone analogs and methods of use |
EA019675B1 (ru) | 2006-02-22 | 2014-05-30 | Эдисон Фармасьютикалз, Инк. | Редокс-активные терапевтические средства для лечения митохондриальных заболеваний и модуляции биомаркера коэнзима q |
US7786100B2 (en) | 2006-03-20 | 2010-08-31 | The Regents Of The University Of Michigan | Composition and method of treating hearing loss |
JPWO2008050829A1 (ja) | 2006-10-26 | 2010-02-25 | 三菱瓦斯化学株式会社 | S−(−)−6−ヒドロキシ−2,5,7,8−テトラメチルクロマン−2−カルボン酸の製造方法及びその方法による製造物 |
CA2674368A1 (en) | 2007-01-10 | 2008-07-17 | Edison Pharmaceuticals, Inc. | Treatment of respiratory chain disorders using compounds having erythropoietin or thrombopoietin activity |
US7745665B2 (en) | 2007-06-04 | 2010-06-29 | Auspex Pharmaceuticals, Inc. | Substituted phenethylamines |
EP2220030B1 (en) | 2007-11-06 | 2016-01-13 | Edison Pharmaceuticals, Inc. | 4- (p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases |
US20100266591A1 (en) | 2008-01-07 | 2010-10-21 | Peter Bugelski | Method of treating erythropoietin hyporesponsive anemias |
WO2009089224A1 (en) | 2008-01-08 | 2009-07-16 | Edison Pharmaceuticals, Inc. | (HET) ARYL-p-QUINONE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES |
WO2009089898A1 (de) | 2008-01-14 | 2009-07-23 | Merck Patent Gmbh | Flüssigkristallines medium |
WO2009111576A2 (en) | 2008-03-05 | 2009-09-11 | Edison Pharmaceuticals, Inc. | 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES |
EP2262519A4 (en) | 2008-03-05 | 2011-03-23 | Edison Pharmaceuticals Inc | TREATMENT OF HEARING AND BALANCE DEFICIENCIES WITH THERAPEUTIC AGENTS WITH REDOX ACTIVITY |
CA2723621A1 (en) | 2008-05-15 | 2009-11-19 | Edison Pharmaceuticals, Inc | Treatment of hearing and balance impairments using compounds having erythropoietin activity |
EP2303309A2 (en) | 2008-05-22 | 2011-04-06 | Edison Pharmaceuticals, Inc. | Treatment of mitochondrial diseases with an erythropoietin mimetic |
JP5266875B2 (ja) | 2008-05-23 | 2013-08-21 | 三菱瓦斯化学株式会社 | 有機カルボン酸エステルからの光学活性有機カルボン酸の製造方法 |
US8716486B2 (en) | 2008-06-25 | 2014-05-06 | Edison Pharmaceuticals, Inc. | 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases |
US20100010100A1 (en) | 2008-07-09 | 2010-01-14 | Hinman Andrew W | Dermatological compositions with anti-aging and skin even-toning properties |
WO2010014361A1 (en) | 2008-07-30 | 2010-02-04 | Edison Pharmaceuticals, Inc. | Naphthoquinone compositions with anti-aging, anti- inflammatory and skin even-toning properties |
WO2010014758A1 (en) | 2008-07-30 | 2010-02-04 | Edison Pharmaceuticals, Inc. | Use of hydrogenated pyrido[4,3-b] indoles for the treatment of oxidative stress |
US8314153B2 (en) | 2008-09-10 | 2012-11-20 | Edison Pharmaceuticals, Inc. | Treatment of pervasive developmental disorders with redox-active therapeutics |
US10039722B2 (en) | 2008-10-14 | 2018-08-07 | Bioelectron Technology Corporation | Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells |
PL2963006T3 (pl) | 2008-10-28 | 2019-01-31 | Bioelectron Technology Corporation | Kompozycja zawierająca chinon alfa-tokotrienolu, i jego związki pośrednie |
KR101496340B1 (ko) | 2008-10-31 | 2015-03-04 | 삼성전자주식회사 | 프로세서 및 메모리 제어 방법 |
CA2760357A1 (en) | 2009-04-28 | 2010-11-04 | Ampere Life Sciences, Inc. | Topical, periocular, or intraocular use of tocotrienols for the treatment of ophthalmic diseases |
CA2759984A1 (en) | 2009-04-28 | 2010-11-04 | Edison Pharmaceuticals, Inc. | Formulation of tocotrienol quinones for the treatment of ophthalmic diseases |
NO2424495T3 (es) | 2009-04-28 | 2018-06-16 | ||
MX2011013558A (es) | 2009-06-25 | 2012-04-30 | Ampere Life Sciences Inc | Tratamiento del trastorno pervasivo del desarrollo con tocotrienoles o extractos de tocotrienoles enriquecidos. |
NO2470168T3 (es) | 2009-08-26 | 2018-06-30 | ||
WO2011041452A2 (en) | 2009-10-01 | 2011-04-07 | Ampere Life Sciences, Inc. | Mouse model for identifying compounds for the treatment of oxidative stress |
EP2519232A1 (en) | 2009-12-31 | 2012-11-07 | Edison Pharmaceuticals, Inc. | Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones |
US8464722B2 (en) | 2010-03-04 | 2013-06-18 | Medline Industries, Inc. | Folded telescopic equipment drape and method of folding and using the same |
US20110263720A1 (en) | 2010-03-09 | 2011-10-27 | Penwest Pharmaceuticals Co. | Synthesis of alpha-tocopherolquinone derivatives, and methods of using the same |
WO2011113018A1 (en) | 2010-03-12 | 2011-09-15 | Ampere Life Sciences, Inc. | Measurement and control of biological time |
AU2011238525A1 (en) | 2010-04-06 | 2012-11-08 | Edison Pharmaceuticals, Inc. | Treatment of Ataxia Telangiectasia |
AU2011245384C1 (en) | 2010-04-27 | 2016-09-01 | Bioelectron Technology Corporation | Formulations of quinones for the treatment of ophthalmic diseases |
WO2012009271A1 (en) | 2010-07-14 | 2012-01-19 | Penwest Pharmaceuticals Co. | Methods of providing anticoagulation effects in subjects |
CA2807507A1 (en) | 2010-08-06 | 2012-02-09 | Edison Pharmaceuticals, Inc. | Treatment of mitochondrial diseases with naphthoquinones |
EP2601168A4 (en) | 2010-08-06 | 2013-12-04 | Ampere Life Sciences Inc | TREATMENT OF MITOCHONDRIAL DISEASES BY VITAMIN K |
US20120295985A1 (en) | 2010-11-19 | 2012-11-22 | Miller Guy M | Methods for improving blood glucose control |
WO2012154613A1 (en) | 2011-05-06 | 2012-11-15 | Edison Pharmaceuticals, Inc. | Improved process for the preparation of d-alpha-tocotrienol from natural extracts |
WO2012170773A1 (en) | 2011-06-08 | 2012-12-13 | Edison Pharmaceuticals, Inc. | Adjunctive therapy for the treatment of mitochondrial disorders with quinones and naphthoquinones |
US9464016B2 (en) | 2011-06-14 | 2016-10-11 | Edison Pharmaceuticals, Inc. | Catechol derivatives for treatment of oxidative stress diseases |
ES2795798T3 (es) | 2011-07-06 | 2020-11-24 | Ptc Therapeutics Inc | Tratamiento de aciduria metilmalónica, aciduria isovalérica, y otras acidurias orgánicas con tocotrienol quinonas |
WO2013006736A1 (en) | 2011-07-06 | 2013-01-10 | Edison Pharmaceuticals, Inc | Treatment of leigh syndrome and leigh-like syndrome, including complications of sucla2 mutations, with tocotrienol quinones |
EP2734512B1 (en) | 2011-07-19 | 2019-11-20 | Bioelectron Technology Corporation | Methods for selective oxidation of alpha tocotrienol in the presence of non-alpha tocotrienols |
CA2841964A1 (en) | 2011-07-20 | 2013-01-24 | Hospira, Inc. | Methods of treating pain |
CA2883882A1 (en) | 2012-09-07 | 2014-03-13 | Edison Pharmaceuticals, Inc. | Benzoquinone derivatives for treating oxidative stress disorders |
CA2902506A1 (en) | 2013-03-08 | 2014-09-12 | Unilever Plc | Resorcinol compounds for dermatological use |
US9670170B2 (en) | 2013-03-15 | 2017-06-06 | Bioelectron Technology Corporation | Resorufin derivatives for treatment of oxidative stress disorders |
US9296712B2 (en) | 2013-03-15 | 2016-03-29 | Edison Pharmaceuticals, Inc. | Resorufin derivatives for treatment of oxidative stress disorders |
US20140275045A1 (en) | 2013-03-15 | 2014-09-18 | Edison Pharmaceuticals, Inc. | Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders |
US9868711B2 (en) | 2013-03-15 | 2018-01-16 | Bioelectron Technology Corporation | Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders |
EP2970158B1 (en) | 2013-03-15 | 2019-02-20 | BioElectron Technology Corporation | Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders |
JP2016520621A (ja) | 2013-05-31 | 2016-07-14 | エジソン ファーマシューティカルズ, インコーポレイテッド | 酸化ストレス障害の処置のためのカルボン酸誘導体 |
JP2018500317A (ja) | 2014-12-16 | 2018-01-11 | バイオエレクトロン テクノロジー コーポレイション | トロロックスのキラル分割のための方法 |
SI3233786T1 (sl) | 2014-12-16 | 2022-08-31 | PTC Therapeutics, Inc., | Polimorfne in amorfne oblike (R)-2-hidroksi-2-metil-4-(2,4,5-trimetil- 3,6-dioksocikloheksa-1,4-dienil)butanamida |
JP2018502127A (ja) | 2015-01-12 | 2018-01-25 | バイオエレクトロン テクノロジー コーポレイション | 放射線被曝に対する防護のためのキノン |
US10745371B2 (en) | 2015-12-16 | 2020-08-18 | Ptc Therapeutics, Inc. | Methods for enriching alpha-tocotrienol from mixed tocol compositions |
US10703701B2 (en) | 2015-12-17 | 2020-07-07 | Ptc Therapeutics, Inc. | Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders |
WO2017123820A1 (en) | 2016-01-12 | 2017-07-20 | Bioelectron Technology Corporation | Methods for diagnosing and treating oxidative stress disorders using biomarkers |
WO2017123823A1 (en) | 2016-01-12 | 2017-07-20 | Bioelectron Technology Corporation | Alkyl-, acyl-, urea-, and aza-uracil sulfide:quinone oxidoreductase inhibitors |
JP6172339B1 (ja) | 2016-06-01 | 2017-08-02 | 三菱ケミカル株式会社 | フィルムインサート成形品の製造方法 |
WO2018081644A1 (en) | 2016-10-28 | 2018-05-03 | Bioelectron Technology Corporation | Methods of analyzing p-hydroquinone levels and ratios |
JP2018083799A (ja) | 2016-11-15 | 2018-05-31 | バイオエレクトロン テクノロジー コーポレイション | 2−置換アミノ−ナフト[1,2−d]イミダゾール−5−オン化合物またはその製薬学上許容される塩 |
WO2018129411A1 (en) | 2017-01-06 | 2018-07-12 | Bioelectron Technology Corporation | Aryl- and heteroaryl-resorufin derivatives for treatment of oxidative stress disorders and liver and kidney disorders |
US20180333389A1 (en) | 2017-04-14 | 2018-11-22 | Bioelectron Technology Corporation | Vitamin e compositions and methods of use therefor |
WO2018191732A1 (en) | 2017-04-14 | 2018-10-18 | Bioelectron Technology Corporation | Methods and compositions for treatment of inflammation and oxidative stress |
JP2022505257A (ja) | 2018-10-17 | 2022-01-14 | ピーティーシー セラピューティクス, インコーポレイテッド | α-シヌクレイノパチー、タウオパチー、および他の障害を抑制および処置するための2,3,5-トリメチル-6-ノニルシクロヘキサ-2,5-ジエン-1,4-ジオン |
EP3983385B1 (en) | 2019-06-13 | 2023-08-30 | PTC Therapeutics, Inc. | Naphthoquinone derivatives for treatment of oxidative stress disorders |
WO2021077034A1 (en) | 2019-10-18 | 2021-04-22 | Ptc Therapeutics, Inc. | 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating hemoglobinopathy, thalassemia, sickle cell disease and other disorders |
-
2008
- 2008-11-04 EP EP08847883.9A patent/EP2220030B1/en active Active
- 2008-11-04 DK DK18198941.9T patent/DK3456707T3/da active
- 2008-11-04 PL PL08847883T patent/PL2220030T3/pl unknown
- 2008-11-04 MX MX2010004622A patent/MX2010004622A/es active IP Right Grant
- 2008-11-04 EA EA201791981A patent/EA038941B1/ru unknown
- 2008-11-04 EP EP18198941.9A patent/EP3456707B1/en active Active
- 2008-11-04 DK DK08847883.9T patent/DK2220030T3/en active
- 2008-11-04 SI SI200832127T patent/SI3456707T1/sl unknown
- 2008-11-04 EP EP15190273.1A patent/EP3018122B1/en active Active
- 2008-11-04 EP EP20169398.3A patent/EP3733642B1/en active Active
- 2008-11-04 SI SI200831577T patent/SI2220030T1/sl unknown
- 2008-11-04 WO PCT/US2008/082374 patent/WO2009061744A2/en active Application Filing
- 2008-11-04 EA EA201000756A patent/EA028911B1/ru not_active IP Right Cessation
- 2008-11-04 HU HUE08847883A patent/HUE028502T2/en unknown
- 2008-11-04 JP JP2010532329A patent/JP5755881B2/ja active Active
- 2008-11-04 PL PL18198941T patent/PL3456707T3/pl unknown
- 2008-11-04 CA CA2704473A patent/CA2704473C/en active Active
- 2008-11-04 US US12/264,838 patent/US7968746B2/en active Active
- 2008-11-04 ES ES08847883.9T patent/ES2564179T3/es active Active
-
2010
- 2010-04-27 MX MX2013012276A patent/MX338572B/es unknown
- 2010-04-27 MX MX2020004146A patent/MX2020004146A/es unknown
- 2010-11-01 HK HK10110222.7A patent/HK1143804A1/zh unknown
-
2011
- 2011-05-18 US US13/110,830 patent/US8519001B2/en active Active
-
2013
- 2013-06-21 US US13/924,363 patent/US9169196B2/en active Active
-
2014
- 2014-02-19 JP JP2014029395A patent/JP2014098025A/ja not_active Withdrawn
-
2015
- 2015-08-18 US US14/829,534 patent/US9546132B2/en active Active
-
2016
- 2016-01-18 JP JP2016006830A patent/JP2016065103A/ja not_active Withdrawn
- 2016-12-09 US US15/374,916 patent/US10167251B2/en active Active
-
2017
- 2017-11-06 JP JP2017213638A patent/JP2018021080A/ja not_active Withdrawn
-
2018
- 2018-12-20 US US16/228,657 patent/US10968166B2/en active Active
-
2019
- 2019-05-15 JP JP2019091932A patent/JP2019131618A/ja not_active Withdrawn
-
2020
- 2020-09-11 JP JP2020152918A patent/JP2020200344A/ja active Pending
-
2021
- 2021-02-22 US US17/249,171 patent/US11840497B2/en active Active
-
2022
- 2022-05-02 JP JP2022075911A patent/JP7291831B2/ja active Active
- 2022-05-02 JP JP2022075910A patent/JP2022093638A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020004146A (es) | Derivados de 4-(p-quinonil)-2-hidroxibutanamida para tratamiento de enfermedades mitocondriales. | |
MX359292B (es) | Sustancias terapeuticas activas redox para el tratamiento de enfermedades mitocondriales y otras condiciones y modulacion de biomarcadores de energia. | |
WO2007100652A3 (en) | Side chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers | |
EA201001119A1 (ru) | Производные (гет)арил-п-хинона для лечения митохондриальных болезней | |
MX2013001469A (es) | Tratamiento de enfermedades mitocondriales con naftoquinonas | |
CY1124526T1 (el) | Συνθεσεις για τη ρυθμιση της εκφρασης αταξινης -2 | |
BR112015023753A2 (pt) | composições, formulações e métodos para o tratamento de doenças oculares | |
CL2019002535A1 (es) | Composiciones para modular la expresión de sod-1.(divisional solicitud 201801897). | |
CO7200281A2 (es) | Composicion para control de enfermedades de plantas y aplicacion para la misma | |
BRPI0720355B8 (pt) | Composições oftálmicas para o tratamento de presbiopia, bem como o uso das mesmas | |
ATE459620T1 (de) | Benzimidazolthiophenverbindungen als plk- modulatoren | |
CU20080027A7 (es) | Bencimidazoles sustituidos como inhibidores de cinasa | |
CR10137A (es) | Agente terapéutico para la diabetes | |
EP4234482A3 (en) | Copper nanoclusters, composition comprising the same, and treatment of neurodegenerative diseases | |
AR068845A1 (es) | Composicion farmaceutica que contiene n-(3-metoxi-5-metilpirazin-2-il)-2-(4-((1,3,4-oxadiazol-2-il))fenil)piridin-3-sulfonamida util para el tratamiento del cancer | |
EA201001128A1 (ru) | Фотозащитные от уф-излучения композиции, прозрачные в видимой области света | |
BRPI0914454A2 (pt) | "composição para o tratamento do tecido epitelial" | |
UY33495A (es) | Derivados de bisaril (tio)morfolina como moduladores s1p | |
NZ593456A (en) | 1-heterodiene derivative and harmful organism control agent | |
WO2014111563A3 (en) | Cosmetic or dermatological composition comprising a merocyanine and a lipophilic benzotriazole uv-screening agent and/or a bis-resorcinyl triazine compound | |
FR3023928B1 (fr) | Charniere pour monture de lunettes | |
MX2018015397A (es) | Co-cristales de benzoato de sodio y sus usos. | |
ATE463229T1 (de) | Haarfärbemittel enthaltend 2-amino-3,5- substituierte phenolverbindungen und deren verwendung | |
PH12017501106A1 (en) | Glasses frame with closed position protecting lenses from impacts or friction | |
BR112012027432A2 (pt) | composições farmacêuticas com agentes antimicrobianos de fosfônio |